Trial Profile
Phase II study of preoperative Docetaxel, cisplatin and S-1 in patients with clinically respectable type 4 , large type 3 and with extensive lymph node metastasis gastric cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Sep 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 03 Mar 2021 Primary endpoint (Pathological response rate, with an expected value of 65%) has not been met as per results published in the Japanese Journal of Clinical Oncology.
- 03 Mar 2021 Results published in the Japanese Journal of Clinical Oncology
- 03 Mar 2021 Status changed from recruiting to completed as per the results published in the Japanese Journal of Clinical Oncology.